REGN

L'intérêt à découvert pour Regeneron Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Regeneron Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock, Rapport sur les intérêts à découvert

REGENERON PHARMACEUTICALS

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals Inc

Regnum Corp

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron Pharmaceuticals, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Lynozyfic (linvoseltamab-gcpt) for adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">least four prior lines of therapy</a>.
Lynozyfic was granted accelerated approval based on response rate and durability of response in the LINKER-MM1 trial. Continued approval for this indication may be contingent upon verification and description of clinical <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46223573/lynozyfic-linvoseltamab-gcpt-receives-fda-accelerated-approval-for-treatment-of-relapsed-or-refrac" rel="noreferrer noopener">benefit in a confirmatory trial</a>.
Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45755748/johnson-johnson-highlights-multiple-blood-cancer-trial-data-at-asco-presentation" rel="noreferrer noopener">Johnson &amp; Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation</a>
The regimen includes hospitalization for safety during the step-up dosing period (one 24-hour period after the first step-up dose, and another 24 hours after the second step-up dose).
The FDA approval for linvoseltamab in R/R MM is based on the pivotal Phase 1/2 LINKER-MM1 trial. In this trial, patients (n=80) experienced a 70% objective response rate (ORR), with 45% achieving a complete response (CR) or better.
The median time to first response was 0.95 months. The median duration of response (DoR) was not reached. Among responders, the estimated DoR was 89% at 9 months and 72% at 12 months, with a median follow-up of 13 months.
The prescribing information for Lynozyfic includes a Boxed Warning for cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome, in addition to warnings and precautions for infections, neutropenia, hepatotoxicity, and embryo-fetal toxicity.
In other news for the company, and highlighting their broader portfolio of approved treatments, in June, the FDA approved Regeneron and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent (dupilumab) for adult patients with bullous pemphigoid (BP), a rare, chronic <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/46028780/fda-approves-regeneronm-sanofi-treatment-for-rare-autoimmune-skin-disorder" rel="noreferrer noopener">autoimmune skin disorder</a>.
BP primarily affects elderly patients and is characterized by intense itch, painful blisters and lesions, and skin reddening. It can be chronic and relapsing with&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46019439/dupixent-dupilumab-approved-in-the-u-s-as-the-only-targeted-medicine-to-treat-patients-with-bullou" rel="noreferrer noopener">underlying type 2 inflammation</a>.
Price Action: REGN stock is trading higher by 0.24% to 549.06 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46242132/crwd-stock-could-soar-16-says-wedbushs-dan-ives-coming-in-very-strong-with-healthy-momentum" target="_blank" rel="noreferrer noopener">CRWD Stock Could Soar 16%, Says Wedbush&#8217;s Dan Ives: &#8216;Coming In Very Strong With Healthy Momentum&#8217;</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Biotech

Large Cap

News

Health Care

General

Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma

WIIM

Regeneron Pharmaceuticals shares are trading higher after the company's Lynozyfic was granted FDA accelerated approval.

Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic&#x2122; (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti‑CD38 monoclonal antibody. Lynozyfic was granted accelerated approval based on response rate and durability of response in the LINKER-MM1 trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy. The regimen includes hospitalization for safety during the step-up dosing period (one 24-hour period after the first step-up dose, and another 24-hour period after the second step-up dose).

Regeneron's Lynozyfic Granted FDA Accelerated Approval For Advanced Multiple Myeloma As First BCMAxCD3 Bispecific Antibody With Extended Dosing Flexibility

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 20 years by 13.87% on an annualized basis producing an average annual return of 22.35%. Currently, Regeneron Pharmaceuticals has a market capitalization of $56.34 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 20 years ago, it would be worth $5,977.36 today based on a price of $521.83 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751400083_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals.
Looking at options history for Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 0% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $777,330 and 7, calls, for a total amount of $257,536.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $300.0 to $680.0 for Regeneron Pharmaceuticals over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Regeneron Pharmaceuticals's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Regeneron Pharmaceuticals's substantial trades, within a strike price spectrum from $300.0 to $680.0 over the preceding 30 days.
<h3>Regeneron Pharmaceuticals Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751396669_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/20/26</td>
<td>$71.0</td>
<td>$65.1</td>
<td>$68.1</td>
<td>$560.00</td>
<td>$340.4K</td>
<td align="right">0</td>
<td align="right">50</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$155.4</td>
<td>$149.3</td>
<td>$152.6</td>
<td>$680.00</td>
<td>$183.1K</td>
<td align="right">25</td>
<td align="right">12</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$132.3</td>
<td>$125.5</td>
<td>$128.0</td>
<td>$650.00</td>
<td>$64.0K</td>
<td align="right">64</td>
<td align="right">5</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$61.8</td>
<td>$54.9</td>
<td>$58.76</td>
<td>$530.00</td>
<td>$58.7K</td>
<td align="right">12</td>
<td align="right">20</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$62.1</td>
<td>$54.8</td>
<td>$58.45</td>
<td>$530.00</td>
<td>$58.4K</td>
<td align="right">12</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Having examined the options trading patterns of Regeneron Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Regeneron Pharmaceuticals's Current Market Status</h3>
<ul>
<li>With a trading volume of 767,808, the price of REGN is up by 2.65%, reaching $538.89.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 31 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Regeneron Pharmaceuticals</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $673.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Regeneron Pharmaceuticals, targeting a price of $650. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Regeneron Pharmaceuticals, targeting a price of $560. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Regeneron Pharmaceuticals, which currently sits at a price target of $800. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Regeneron Pharmaceuticals, maintaining a target price of $755. 
&#x2A; An analyst from BMO Capital persists with their Outperform rating on Regeneron Pharmaceuticals, maintaining a target price of $600. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Regeneron Pharmaceuticals Unusual Options Activity For July 01

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) released on Tuesday statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD <a href="https://www.benzinga.com/news/health-care/25/06/46074205/nektar-therapeutics-shares-double-on-promising-eczema-drug-data" target="_blank" rel="noreferrer noopener">study of investigational rezpegaldesleukin</a>.
The trial met its primary endpoint of the <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">mean improvement in Eczema</a> Area and Severity Score (EASI) from baseline at week 16 for all three dose arms of rezpegaldesleukin versus placebo.
All three dose arms also achieved statistical significance at week 16 for the key secondary endpoints of EASI-75 (percent of patients who achieve ≥75% reduction in EASI from baseline), EASI-50 (percent of patients who achieve ≥50% reduction in EASI from baseline) and BSA (mean percent improvement in Body Surface Area score from baseline).
Also Read: <a href="https://www.benzinga.com/news/health-care/25/06/46074205/nektar-therapeutics-shares-double-on-promising-eczema-drug-data" target="_blank" rel="noreferrer noopener">Nektar Therapeutics Shares Double On Promising Eczema Drug Data</a>
After 16 weeks, patients had a 53% to 61% improvement in symptoms. This was compared to a 31% improvement for the placebo group.
William Blair writes, &#8220;We believe the efficacy parameters of rezpeg appear to be comparable to the OX40 drug class though numerically lower than Dupixent across the Phase IIb programs.&#8221;
Given the chronic nature of atopic dermatitis, analyst Andy Hsieh wrote that the high frequencies (high 30% to high 40% across a broader set of rezpeg safety data that includes the Phase 2b results) of injection site reactions versus Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)/Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent (in the high-single- to mid-double-digit percent range) could be a commercial liability for rezpeg.
If rezpeg indeed demonstrates a remittive effect, it could mitigate injection site reactions, though investors will have to wait until the next update (Phase IIb REZOLVE-AD maintenance data) in early 2026 or 52-week off-treatment results in 2027.
The analyst adds, &#8220;Since we believe there is an absence of clear differentiation in the highly competitive atopic dermatitis field, we view today's stock reaction (up roughly 135%) as a valuation normalization event and not a reflection of investors ascribing value to a differentiated asset. Essentially, Nektar shares now trade around the company's current cash levels. We await further updates to gain appreciation of rezpeg&#8217;s potential remittive effect, which could elevate the asset against competitive offerings.&#8221;
NKTR Price Action: Nektar Therapeutics stock is up 26.83% at $31.01 at publication on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46097909/robinhood-ceo-highlights-retail-investor-interest-in-nvidia-tesla-despite-middle-east-tensions-barely-a-blip" target="_blank" rel="noreferrer noopener">Robinhood CEO Highlights Retail Investor Interest In Nvidia, Tesla Despite Middle East Tensions: &#8216;Barely A Blip&#8217;</a></li>
</ul>

Analyst Color

Analyst Ratings

Movers

NKTR

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?

Regeneron Launches $200M Donation Matching Program With Good Days To Expand Access To Vision-Saving Treatments In 2025

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 20 years by 14.22% on an annualized basis producing an average annual return of 22.54%. Currently, Regeneron Pharmaceuticals has a market capitalization of $55.03 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 20 years ago, it would be worth $6,185.92 today based on a price of $509.72 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750453216_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent&nbsp;(dupilumab) for adult patients with bullous pemphigoid (BP), a rare, chronic <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">autoimmune skin disorder</a>.
BP primarily affects elderly patients and is characterized by intense itch, painful blisters and lesions, and skin reddening. It can be chronic and relapsing with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46019439/dupixent-dupilumab-approved-in-the-u-s-as-the-only-targeted-medicine-to-treat-patients-with-bullou" rel="noreferrer noopener">underlying type 2 inflammation</a>.
The blisters and rash can form over much of the body and cause the skin to bleed and break down, making patients more prone to infection.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45692578/regeneron-sanofi-stock-falls-after-uneven-smokers-lung-drug-data" rel="noreferrer noopener">Regeneron, Sanofi Stock Falls After Uneven Smoker&#8217;s Lung Drug Data</a>
The FDA approval is based on data from the pivotal ADEPT Phase 2/3 trial that evaluated the efficacy and safety of Dupixent compared to placebo in adults with moderate-to-severe BP.
Patients were randomized to receive Dupixent 300 mg (n=53) or placebo (n=53) added to standard-of-care oral corticosteroids (OCS).
During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained.
The FDA-approved results at 36 weeks in the label for Dupixent compared to placebo are:
<ul class="wp-block-list">
<li>18.3% of patients experienced sustained disease remission compared to 6.1%, the primary endpoint.</li>
<li>38.3% of patients achieved clinically meaningful itch reduction compared to 10.5%.</li>
<li>The median cumulative OCS dose was 2.8 grams compared to 4.1 grams.</li>
</ul>
In this elderly population, the most common adverse events (≥2%) more frequently observed in patients on Dupixent compared to placebo were arthralgia, conjunctivitis, blurred vision, herpes viral infections, and keratitis.
Additionally, one acute generalized exanthematous pustulosis was reported in 1 patient treated with Dupixent and zero treated with placebo.
In April, the FDA approved Dupixent&nbsp;for adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-d" rel="noreferrer noopener">antihistamine treatment</a>.
Price Action: REGN stock closed at $513.58 on Wednesday. SNY stock is up 1.45% at $48.31&nbsp;during the premarket session at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45724030/kymera-therapeutics-says-atopic-dermatitis-potential-matches-sanofi-regenerons-blockbuster-dupixent-in-early-biomarker-response" target="_blank" rel="noreferrer noopener">Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron&#8217;s Blockbuster Dupixent In Early Biomarker Response</a></li>
</ul>
Image: Shutterstock

FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder

Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent&#xAE; (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP).
BP primarily affects elderly patients, and is characterized by intense itch, painful blisters and lesions, as well as reddening of the skin. It can be chronic and relapsing with underlying type 2 inflammation. The blisters and rash can form over much of the body and cause the skin to bleed and break down, resulting in patients being more prone to infection and affecting their daily functioning. Available treatment options are limited and can add to overall disease burden by suppressing a patient's immune system.
"People affected by bullous pemphigoid endure unrelenting itch and painful blisters that can damage the skin. Until now, these primarily elderly patients have had limited therapeutic options available, with potential side effects that have often added to their burden," Patrick Dunn, Executive Director at the International Pemphigus and Pemphigoid Foundation. "The approval of Dupixent for bullous pemphigoid brings a novel treatment approach to patients and their caregivers, and we are grateful for the tireless efforts of the scientific community who helped us reach this critical milestone."
"Today's approval extends the remarkable ability of Dupixent to transform treatment paradigms for people living with a variety of diseases with underlying type 2 inflammation, from common conditions like asthma and atopic dermatitis, to rarer ones such as eosinophilic esophagitis and prurigo nodularis, and now including bullous pemphigoid," said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. "Dupixent has shown the potential to improve the most challenging effects of bullous pemphigoid, while helping some patients achieve sustained disease remission and decreased oral corticosteroid use. Additionally, this approval further reinforces the demonstrated safety profile of Dupixent in a broad age range of patients, from infants to elderly people, and across dermatological, respiratory and gastrointestinal diseases."
The FDA approval is based on data from the pivotal ADEPT Phase 2/3 trial that evaluated the efficacy and safety of Dupixent compared to placebo in adults with moderate-to-severe BP. Patients were randomized to receive Dupixent 300 mg (n=53) or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained. During the FDA review, the analyses were updated; the FDA-approved results at 36 weeks in the label for Dupixent compared to placebo are:
<ul>
<li>18.3% of patients experienced sustained disease remission compared to 6.1% (12.2% difference; 95% confidence interval: -0.8% to 26.1%), the primary endpoint</li>
<li>38.3% of patients achieved clinically meaningful itch reduction compared to 10.5%</li>
<li>Median cumulative OCS dose was 2.8 grams compared to 4.1 grams &nbsp;</li>
</ul>
In this elderly population, the most common adverse events (≥2%) more frequently observed in patients on Dupixent compared to placebo were arthralgia, conjunctivitis, blurred vision, herpes viral infections and keratitis. Additionally, 1 case of acute generalized exanthematous pustulosis was reported in 1 patient treated with Dupixent and 0 patients treated with placebo.

Government

Regulations

Regeneron and Sanofi Win FDA Approval for Dupixent to Treat Painful Skin Disease in Elderly Patients

Scholar Rock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-<a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">induced weight loss</a>.
Tirzepatide is an active ingredient in Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) widely used Mounjaro and Zepbound for diabetes and weight loss, respectively.
The trial demonstrated that 30% of the total weight loss with tirzepatide alone was <a href="https://www.benzinga.com/pressreleases/25/06/b45991772/scholar-rock-reports-positive-phase-2-embraze-trial-results-demonstrating-statistically-significan" target="_blank" rel="noreferrer noopener">due to lean mass loss</a>.
Apitegromab therapy (10 mg/kg) with tripeptide preserved an additional 4.2 pounds (1.9 kilograms) or 54.9% (p=0.001) of lean mass compared to tripeptide alone, leading to higher-quality weight loss.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44359926/scholar-rock-stock-jumps-on-additional-data-from-pivotal-trial-of-muscular-dystrophy-treatment" rel="noreferrer noopener">Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment</a>
The study showed that 30.2% of the total weight loss with tirzepatide, the ingredient in Zepbound, was due to lean mass loss.
According to 24-week data, adding 10 mg/kg apitegromab therapy to the tripeptide regimen halved the proportion of lean mass lost to 14.6%.
The company described the apitegromab-tirzepatide combo as "higher quality of weight loss." Specifically, these patients lost 85% and 15% of their fat and lean mass, respectively, while the ratio for the&nbsp;tirzepatide-placebo cohort was 70% and 30%.
Regarding total weight loss, patients on apitegromab-tirzepatide saw their weight drop by 12.3% compared to 13.4% for those on tirzepatide-placebo.
Apitegromab with tirzepatide was generally well tolerated by participants.
Earlier in June, Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)&nbsp;released interim results from the ongoing Phase 2 COURAGE trial investigating combinations of&nbsp;Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy (semaglutide) (GLP-1&nbsp;receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or without garetosmab&nbsp;<a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" rel="noreferrer noopener">(anti-activin A) for obesity</a>.
The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass.
Last week, Juvena Therapeutics Inc. announced global licensing and&nbsp;multi-target research collaboration&nbsp;with&nbsp;Eli Lilly. The two companies aim to develop and commercialize drug candidates that improve&nbsp;<a href="https://www.benzinga.com/news/health-care/25/06/45887444/eli-lilly-inks-pact-with-juvena-therapeutics-to-develop-muscle-boosting-drugs" target="_blank" rel="noreferrer noopener">muscle health and body composition</a>.
Price Action: SRRK stock is up 18% at $36.77 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45947852/eli-lilly-launches-flat-pricing-for-zepbound-capping-monthly-cost-at-499" target="_blank" rel="noreferrer noopener">Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499</a></li>
</ul>
Photo: Shutterstock

SRRK

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

23ANDME HOLDING CO A by 23andMe Holding Co.

MEHCQ

Reuters Cites Regeneron Pharmaceuticals On 23andme Bid Saying Declined To Submit A New Bid Exceeding Original Winning Bid Of $256M

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases, <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">including obesity</a>.
Under the terms of the agreement, Deep Apple <a target="_blank" href="https://deepappletx.com/deep-apple-therapeutics-announces-collaboration-with-novo-nordisk-to-discover-and-develop-oral-therapeutics-for-cardiometabolic-diseases/" rel="noreferrer noopener">will</a> discover and optimize compounds using its proprietary drug discovery platform, which combines machine-learning-powered virtual screening with structural biology enabled by cryo-electron microscopy (cryo-EM) to dramatically improve speed, quality, and novelty in lead generation and optimization.
Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in all indications.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45814068/novo-nordisks-wegovy-tied-to-increased-risk-of-rare-vision-loss-disorder-european-regulators-say" rel="noreferrer noopener">Novo Nordisk&#8217;s Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say</a>
Both companies will collaborate on the research plan, with program handoff to Novo Nordisk occurring immediately before the start of IND-enabling studies.
Deep Apple is eligible to receive an upfront payment, research costs, and milestone payments from Novo Nordisk.
Deep Apple will be eligible to receive up to $812 million in payments and potential royalties on sales of any products that emerge from the collaboration.
Recently, the Danish pharma giant <a target="_blank" href="https://clinicaltrials.gov/study/NCT07011667?cond=CAGRISEMA&amp;sort=StudyFirstPostDate&amp;rank=1" rel="noreferrer noopener">initiated</a> a Phase 3 trial to evaluate the efficacy and safety of cagrilintide sc combined with semaglutide sc (CagriSema&nbsp;sc) once weekly for weight management and long-term weight maintenance in obese participants.
The two-part study in around 600 participants will last about 3 years and 3 months.
In March, Novo Nordisk announced headline results from the REDEFINE 2 phase 3 trial in the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44244966/novo-nordisks-combo-drug-cagrisema-shows-16-weight-reduction-in-second-phase-3-trial-stock-falls" rel="noreferrer noopener">global REDEFINE program</a>.
REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema compared to placebo.
After 68 weeks, 61.9% of patients treated with CagriSema were on the highest dose.
When evaluating treatment effects, if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 15.7% after 68 weeks compared to 3.1% with placebo.
Last week, Regeneron Pharmaceuticals, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) released interim results from the ongoing Phase 2 COURAGE trial evaluating Regeneron&#8217;s trevogrumab (anti-GDF8/anti-myostatin) with semaglutide (GLP-1&nbsp;receptor agonist) with or without garetosmab&nbsp;<a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" rel="noreferrer noopener">(anti-activin A) for obesity</a>.
The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to the loss of lean mass.
Price Action: NVO stock is up 0.04% at $79.36&nbsp;at the last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45834370/eli-lillys-obesity-drug-success-spurs-japanese-biotechs-anti-muscle-wasting-combo-therapy" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Obesity Drug Success Spurs Japanese Biotech&#8217;s Anti-Muscle-Wasting Combo Therapy</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Contracts

Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies

REGN climbs over 16 points after the alert
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/09204238/Screenshot-2025-06-09-at-4.39.08%E2%80%AFPM-994x1024.png" alt="" class="wp-image-14161" /></figure>
Regeneron Pharma Inc. (REGN) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:16AM on June 9th, a significant trading signal occurred for Regeneron Pharma Inc., (REGN) as it demonstrated a Power Inflow at a price of $501.83. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Regeneron&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Regeneron's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for REGN, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025</a>, which are responsible for parts of the data within this article.
The price at the time of the Power Inflow was $501.83. The returns on the High price ($517.91) and Close price ($517.60) after the Power Inflow are respectively 3.2% and 3.1%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. They were very close today, but that is not always the case.
Past performance is not indicative of future results

Equities

Technicals

Opinion

Signals

Regeneron Pharma Shares Rise Over 3% After Key Signal

Regeneron Pharmaceuticals shares are trading higher. A company executive reportedly said the 23andMe auction process was recently reopened and that the tariff situation is not "material" to the business.

JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $950 to $800.

Price Target

JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $800

<a href="https://investor.regeneron.com/events/event-details/46th-annual-goldman-sachs-global-healthcare-conference" title="https://investor.regeneron.com/events/event-details/46th-annual-goldman-sachs-global-healthcare-conference">https://investor.regeneron.com/events/event-details/46th-annual-goldman-sachs-global-healthcare-conference</a>

Global

Watching Regeneron; At Goldman Sachs Conference, Exec Reportedly Says 23andMe Auction Process Was Recently Reopened And Is "Fairly Complicated"; Says Tariff Situation Currently Enacted Is Not "Material" To Business, But Sectoral Tariffs Could Have An Impact

French drugmaker Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">runs through March</a>.
Sanofi, in collaboration with its partner AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023.
Immunizations <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-09-05-00-00-3095598" rel="noreferrer noopener">begin</a> in early fall. The current supply for the upcoming season matches the total doses distributed last year, and production continues.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" rel="noreferrer noopener">Regeneron&#8217;s Obesity Trial With Novo Nordisk&#8217;s Wegovy Hits Lean Target</a>
Sanofi said Beyfortus duration of protection was extended for six months in the EU. This year&#8217;s EU shipments are marked by an important change to the Beyfortus EU label, extending the duration of protection through six months so Beyfortus can continue to offer season-long protection for all infants, including older babies immunized just before the RSV season begins.
More than six million babies have been immunized worldwide, and millions more will be immunized this season in more than 40 countries to help protect them from the potentially devastating impact of RSV disease.
In another development, Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi on Saturday presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent&nbsp;(dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45828306/dupixent-dupilumab-data-at-revolutionizing-atopic-dermatitis-rad-conference-reinforce-use-in-atopi" rel="noreferrer noopener">with skin of color</a>.
These are the first clinical trial results for Dupixent in a large population of patients with darker skin tones.
The results, along with the Dupixent Phase 3 trials, demonstrated patients taking Dupixent experienced improvements in signs and symptoms of atopic dermatitis from baseline across many skin tones.
The data were shared at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference. In the trial, 120 patients with atopic dermatitis and skin of color were treated with Dupixent every two weeks using a weight-based dosing regimen.
At 24 weeks:
<ul class="wp-block-list">
<li>76% achieved a ≥75% improvement in overall disease severity (EASI-75), the primary endpoint. Some patients saw improvements as early as two weeks.</li>
<li>53% achieved clinically meaningful improvement in itch (≥4-point reduction on the peak-pruritus numerical rating scale [PP-NRS]). Improvements were seen by some patients as early as two weeks.</li>
<li>Patients experienced a 53% reduction from baseline in post-inflammatory hyperpigmentation, dropping from 5.1 points (moderate/marked) to 2.4 points (mild).</li>
<li>Based on patient reporting, 18% were very or extremely bothered by dry skin, compared to 78% at baseline.</li>
<li>The safety results in the DISCOVER trial were generally consistent with the known safety profile of Dupixent in its approved dermatological indications.</li>
</ul>
Price Action: REGN stock was trading higher by 1.53% to $500.75, and SNY stock was down 0.99% at $49.97.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45817049/arcutis-unveils-long-term-efficacy-safety-for-zoryve-cream-in-pediatric-patients-with-atopic-dermatitis" target="_blank" rel="noreferrer noopener">Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis</a></li>
</ul>
Photo by HJBC via Shutterstock

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season

<ul>
<li>Atopic dermatitis is a chronic disease that disproportionately impacts communities of color</li>
<li>Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of treated patients</li>
<li>Patients experienced substantial reductions in hyperpigmentation, dry skin and itch from baseline</li>
<li>Results support commitment to enhance clinical understanding of chronic diseases in communities of color</li>
</ul>

Reported Saturday, Sanofi And Regeneron Present New Dupixent Results Highlighting Disease Severity Reduction In Patients With Darker Skin Tones

MAIA Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAIA#NASDAQ">MAIA</a>) on Thursday revealed updated data from its THIO-101 pivotal <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45790333/maia-biotechnology-announces-positive-efficacy-update-for-phase-2-thio-101-clinical-trial-in-non-s" rel="noreferrer noopener">Phase 2 clinical trial</a>.
The trial is evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron Pharmaceutical Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) immune checkpoint inhibitor (CPI) cemiplimab (Libtayo) for advanced non-small cell lung cancer (NSCLC) who are resistant to immune <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">therapy and chemotherapy</a>.
As of May 15, third line (3L) data showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine (the intent-to-treat population) in parts A and B of the trial. The updated analysis demonstrates a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39909095/maia-biotechnologys-lung-cancer-drug-shows-promising-long-term-benefits-in-advanced-patients" rel="noreferrer noopener">MAIA Biotechnology&#8217;s Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients</a>
The treatment has been generally well-tolerated to date in this heavily pretreated population.
At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival.
Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.
&#8220;This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC found in the medical literature. We believe this is a substantial indicator of the potential ateganosine has to shift the NSCLC treatment landscape,&#8221; said MAIA Chairman and CEO Vlad Vitoc.
MAIA&#8217;s multiple potential regulatory pathways for ateganosine could provide accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year.
The company announced a new partial response (PR) was identified in a patient after 20 months of treatment. A partial response is defined as a decrease in tumor size of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45796236/maia-biotechnology-announces-new-responder-in-non-small-cell-lung-cancer-phase-2-clinical-trial" rel="noreferrer noopener">at least 30%</a>.
&#8220;The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment,&#8221; Vitoc added.
Price Action: MAIA stock is up 11.7% at $1.97 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45800081/dr-reddys-and-alvotech-join-hands-to-develop-biosimilar-for-mercks-blockbuster-cancer-drug">Dr Reddy&#8217;s And Alvotech Join Hands To Develop Biosimilar For Merck&#8217;s Blockbuster Cancer Drug</a></li>
</ul>
Photo via Shutterstock

MAIA

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

Press Releases

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry

23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

ANIX

IBRX

IOVA

ONCY

PARIS:SAN

TSX:ONC

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

Regeneron Pharmaceuticals

Intérêt court

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL